Overview

Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

This is a prospective, open controlled trial in which HIV-1 with viral suppression patients will be randomized to continue with their current treatment (lopinavir/ritonavir plus emtricitabine or lamivudine plus any nucleoside analogue reverse transcriptase inhibitor) or to simplify to lopinavir/ritonavir plus lamivudine. Randomization will be stratified according to the values of nadir CD4 and time of viral suppression.

Phase:

Phase 4

Details

Lead Sponsor:

Juan A. Arnaiz

Treatments:

Anti-Retroviral Agents
Lamivudine
Lopinavir
Ritonavir